Efalizumab

N/A

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameEfalizumab
Drug Alias NameXanelim依法珠单抗Humanized MHM24依法利珠单抗anti-CD11a MAb +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukocyte adhesion glycoprotein LFA-1 alpha antagonists
TargetsLeukocyte adhesion glycoprotein LFA-1 alpha
Therapy Area/IndicationsPlaque psoriasisPalmoplantar pustulosisDiabetes Mellitus, Type 1 +[10] 
Global Approved IndicationsPsoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2003/10/27
Country/TerritoryUnited StatesSwitzerlandEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Medicine And Dentistry Of New JerseyOregon Health And Science UniversityNational Institute Of Dental And Craniofacial Research (Nidcr) +[10] 
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisPalmoplantar pustulosisDiabetes Mellitus, Type 1 +[10] 

Other Information

ATC CodeL04AG02
Related LinksWikipediaDrugBankKEGG